Arterial Stiffness in Chronic Kidney Disease: The Usefulness of a Marker of Vascular Damage by Bellasi, Antonio et al.
SAGE-HindawiAccess to Research
International Journal of Nephrology
Volume 2011, Article ID 734832, 5 pages
doi:10.4061/2011/734832
Review Article
ArterialStiffnessin ChronicKidneyDisease:TheUsefulness of
aMarkerofVascularDamage
Antonio Bellasi,1 EmilianaFerramosca,1 and CarloRatti2
1Division of Nephrology, S.Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy
2Division of Cardiology, Ospedale di Mirandola, 41121 Modena, Italy
Correspondence should be addressed to Antonio Bellasi, antoniobellasi@hotmail.com
Received 23 March 2011; Accepted 27 March 2011
Academic Editor: Biagio Raﬀaele Di Iorio
Copyright © 2011 Antonio Bellasi et al.Thisisanopenaccessarticledistributed undertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Increased arterial stiﬀness is a marker of vasculopathy in chronic kidney disease (CKD) patients, suggesting a signiﬁcant
cardiovascular damage. Detection of arterial stiﬀness provides physicians with useful prognostic information independent of
traditional cardiovascular (CV) risk factors. In addition, this knowledge may help guide appropriate therapeutic choices and
monitor the eﬀectiveness of antihypertensive therapies. We review the relationship between arterial stiﬀness and CKD, as well as
the prognostic implicationsof increased arterial stiﬀness and the potential therapeutic strategies to ameliorate arterial compliance
and outcome in CKD.
1.Introduction
Traditional CV risk factors are of major importance to
identify subjects at risk for cardiovascular disease (CVD).
However, in spite of a signiﬁcant over-representation, tradi-
tional CV risk factors do not accurately predict survival in
CKD patients. Hence, severalnew biomarkers of CV risk and
disease have been identiﬁed in the hope to reﬁne the CV risk
assessment.
It is important to diﬀerentiate between circulating
and tissue biomarkers. Serum concentration of circulating
biomarkers may vary substantially according to the instant
risk at which an individual is exposed. Nevertheless, several
factors may inﬂuence and confound their serum levels, and
a recent article questioned the added value of the use of
multiple serum biomarkers to reﬁne the risk assessment and
outcome prediction [1].
To the contrary, tissue biomarkers such as vascular
calciﬁcation or arterial stiﬀness are signs of true tissue
damage rather than risk factors. In other words, they reﬂect
the cumulative exposure to damaging factors that have
harmed the cardiovascular system. Notably, a growing body
of evidence suggests that tissue biomarkers can be useful
in combination with traditional CV risk factors to assess
the CV risk of a single individual. Indeed, arterial stiﬀness
or vascular calciﬁcation evaluation adds a signiﬁcant and
independent contributionin the prediction of microvascular
damage of the heart, brain, retina, and kidney as well as CV
outcome.
The usefulness of a biomarker depends on its accuracy
in detecting the disease and in guiding treatment. The aim
of this paper is to summarize the available evidence that
supports the use of arterial stiﬀness assessment in CKD
patients.
2.VascularRemodelingandArterialStiffness
Large central arteries play a key role in converting the pul-
satile cardiac outﬂow into a continuous blood ﬂow through-
out the arterial tree. In systole, the heart pushes a volume
of blood (i.e., stoke volume) into the thoracic aorta (ejection
phase). Becauseﬂuidsare uncompressible, thestroke volume
distends the thoracic aorta. By stretching, the arterial wall
accumulates the elastic energy that maintains the blood ﬂow
during diastole when the ejection phase is over (Windkessel2 International Journal of Nephrology
eﬀect). Thus, the pulsatile ﬂow is converted into a contin-
uous ﬂow by the cyclic distention and recoiling of central
arteries.
The muscular and endothelial cells as well as other
components of the arterial wall have to adapt to the diﬀerent
stimuli to which they are exposed to maintain an adequate
blood perfusion during diastole. However, aging, increase in
the mean arterial pressure, diabetes, or other noxious factors
exposure induces vascular structure and function changes
that ultimately may lead to arterial wall stiﬀness increase.
In this regard, a few lines of evidence suggest that expo-
sure to traditional and nontraditional CV risk factors leads
to arterial wall remodeling and reduced arterial compliance.
All these changes negatively aﬀect the process that converts
the pulsatile in continuous blood ﬂow impairing the oxygen
supply to peripheral tissues.
T h u s ,a r t e r i a ls t i ﬀness might be considered as a measure
of arterial damage due to the cumulative exposure of aging
and diﬀerenttraditional and non-traditional CVrisk factors.
3.ArterialStiffnessand ChronicKidney
Disease:A ViciousCycle
Many clinical and epidemiological studies have documented
that patients with impaired kidney function are at increased
risk of CV events and mortality [2]. Notably, the association
of CKD and CV events is signiﬁcant even with mild decre-
ments of renal function not suﬃciently severe to result in
elevated serum creatinine [3].
The mechanisms responsible for this strong association
are not well established. However, a few lines of evidence
suggest that arterial stiﬀness increases with progressive
worsening of renal function. A seminal paper by Wang
and coworkers [4] showed a clinically meaningful increase
in the aortic pulse wave velocity (PWV), an accurate and
reproducible parameter of arterial stiﬀness, with estimated
glomerularﬁltration rate (eGFR)decline.In thisstudy, while
PWV was comparable between age-matched controls and
CKD1-2 patients, there was a signiﬁcant trend for a stepwise
increase in PWV with more advanced stages of CKD (3
through 5). Notably, multivariable analyses conﬁrmed the
independent association between eGFR and PWV [4].
This observation was conﬁrmed by other studies. Ix and
coworkers [5] demonstrated in a large cross-sectional study
of4,513 individuals from the general populationthat arterial
stiﬀness assessed via the ankle-brachial index (ABI) was
associated with even mild impairments of the renal function
(i.e., eGFR below 80mL/min) estimated by Cystatin-C.
In spite of adjustment for age, sex, race, hypertension,
diabetes, smoking, body mass index, LDL cholesterol, HDL
cholesterol, and CRP, values of eGFR below 80mL/min
were associated with high ABI (RR 1.6; 95% CI 1.0–2.3;
P = .03). Notably, these results were similar when CKD
was deﬁned by creatinine. Another study by Makita et al.
[6] further expanded the observation by documenting that
arterial stiﬀness increases in early CKD stages even in the
absence of disease of the intimal layer of the arterial wall and
independently of traditional CV risk factors [6].
The link between CKD and arterial stiﬀness is further
complicated by the fact that arterial stiﬀness may promote
CKD progression [7–9]. Though evidence is far from being
conclusive, Tomiyama et al. [9] noted that higher brachial-
ankle pulse wave velocity (baPWV) was associated with
greater annual rate of eGFR decline in a large cohort of 2053
Japanese subjects. Every increase of 1m/s in baseline baPWV
was associated with a 36% greater risk of having the GFR
dropping below 60mL/min at followup (odds ratio 1.36;
95% conﬁdence interval: 1.09–1.70; P<. 01). In contrast,
baseline eGFR did not seem to be associated with the annual
rate of change in baPWV suggesting that elevated arterial
stiﬀness may also be an independent predictor of renal
function decline [9].
4.ArterialStiffnessasaMarker of
CV Diseaseand PoorCV Prognosis
As a marker of cardiovascular disease, increased arterial
stiﬀness is linked to several other markers of CV dysfunction
such as microalbuminuria and proteinuria, vascular calciﬁ-
cation (VC), and left ventricular hypertrophy (LVH).
A few lines of evidence suggest that albuminuria, a
recognized marker of vascular dysfunction, is associated
with arterial stiﬀness. In a large observational study of 2180
patients, Liu and coworkers [10] noted a signiﬁcant trend
(P<. 001)towardahigherprobabilityofhavingalbuminuria
associated with higher brachial-ankle pulse wave velocity
(baPWV). When compared to the lowest quartile of baPWV,
the adjusted odds ratios of having albuminuria during the
followup were 1.12 (95% CI:0.63–2.02),2.04 (95% CI:1.15–
3.60),and2.45(95%CI:1.29–4.65)forthesecond,third,and
fourth quartile of baPWV, respectively. Notably, the strength
of the association between baPWV and microalbuminuria
was not attenuated by multiple adjustments for potential
confounders and was enhanced in diabetic and hypertensive
patients [10].
A signiﬁcant link between aortic PWV and vascular
calciﬁcationburdenhasalsobeendescribedinCKDpatients.
In a previous work [11], we showed that CKD patients
receiving dialysis with great calciﬁcation burden in the
abdominal aorta were more likely to have a signiﬁcantly
higher PWV. Adjustment for several confounders did not
signiﬁcantly aﬀect this association [11]. In another paper
by Di Iorio et al. [12], every 20 units increase in CACS
corresponded to a signiﬁcant 23% (95% CI: 1.12–1.27;
P<. 001) increase in the risk of experiencing 1m/sec
increase in PWV during follow-up. Interestingly the link
between arterial stiﬀness and the chronic kidney disease-
mineral bone disorder (CKD-MBD) syndrome might not be
limited tovascularcalciﬁcation.Indeed,datafrom theMulti-
Ethnic Study of Atherosclerosis (MESA) study show that
higher phosphorous levels are strongly associated with the
ankle-brachial index (ABI). A phosphorous level >4mg/dL
compared with <3.0mg/dL was associated with a signiﬁcant
fourfold increased risk for high ABI (>1.3)(relative risk:4.6;
95% CI 1.6–13.2; P = .01) [13].International Journal of Nephrology 3
A few cross-sectional studies [14–16] and a recent ran-
domized controlled trial (RCT) [17] support the hypothesis
of a strong connection between arterial stiﬀness and left
ventricleand atrium remodeling.Indeed,lower arterial com-
pliance increases aortic pulse pressure and the cardiac work-
load possibly leading to left ventricular hypertrophy (LVH)
and dysfunction. Nitta and coworkers [14]d o c u m e n t e da
signiﬁcant correlation between LVH and PWV (r = 0.44,
P = .0014) in a small series of 49 patients receiving dialysis.
A subsequent paper [18] showed in a cohort of CKD stage 2
and 3 patients that aortic distensibility and LV mass assessed
by cardiac magnetic resonance were inversely associated (r =
0.349, P<. 01) [18]. Notably, examinations of patients
and controls showed that arterial elastance (a measure of
aortic stiﬀness) and end-systolic elastance (a measure of left
ventricular stiﬀness) were signiﬁcantly correlated (r = 0.692,
P<. 001) underscoring the association between arterial
stiﬀness and cardiac function [18]. Finally, a recent RCT
[17] documented that the addition of spironolactone on top
of ACE inhibitors or angiotensin receptor blockers (ARBs)
attenuates both left ventricular hypertrophy and arterial
stiﬀness.
Low arterial compliance has been associated with an
excess of morbidity and mortality in the general population
and inCKDpatients[19, 20].In a seminal study, Blacherand
coworkers [20] documented that aortic stiﬀness determined
by measurement of aortic PWV was linearly associated with
all-cause and CV mortality in a cohort of 241 patients
undergoing maintenance dialysis (adjusted odds ratio per
1m/sec increase in all-cause mortality: 1.39: 95% CI, 1.19 to
1.62). Similar results were reached in a larger series of 1084
patients receiving dialysis recruited in the CORD study [21].
Indeed, each 1m/s increase in PWV was associated with a
signiﬁcant 15% higher risk of dying during the 24months of
follow-up [21]. Of interest is that adjusting for age, diabetes,
and serum albumin did not attenuate these results [21].
5.Therapeutic Approaches to Arterial Stiffness
and Impact of Arterial Stiffness Attenuation
onSurvival
A few therapeutic approaches have been attempted to reduce
arterial stiﬀness both in the general population and in CKD
patients.
Agents that modulate mineral metabolism abnormal-
ities may positively aﬀect arterial stiﬀness. Two small
observational studies showed that the use of Sevelamer, a
noncalcium-containing phosphate binder, may signiﬁcantly
attenuate PWV deterioration in CKD patients receiving
chronic dialysis [22, 23]. In another small series of 132
patients new to dialysis, the use of Sevelamer was associated
with a signiﬁcant reduction in the risk of PWV increase
during the ﬁrst 12months of dialysis (odds ratio: 0.86;
95%CI 0.83–0.91, P = .05) [12]. Cinacalcet may also
reducearterialstiﬀness inhemodialysispatients[24].Indeed,
Bonet and coworkers [24] in a small-scale prospective and
observational study noted that cinacalcet administration to
21 patients resulted in a signiﬁcant reduction of PWV after
12 months (9.35 (1.83) versus 8.66 (1.86)m/sec; P = .03;
before and after treatment).
Somepreliminary datasuggestthatLipidlowering agents
may also lower arterial stiﬀness. In a recent RCT [25],
37 CKD stage 2–4 patients were selected to receive 10mg
atorvastatin or placebo for 3 years. At study completion,
aortic PWV showed a signiﬁcant increase over time in
placebo-treated butnot inatorvastatin-treated patients(0.51
(0.95) versus 0.30 (0.75)m/sec per year in placebo- and
atorvastatin-treated patients, resp.) [25]. Of importance is
that these promising results were not conﬁrmed in an
ancillary study entitled the Anglo-Scandinavian Cardiac
Outcomes Trial (ASCOT) [26]. In this study, 891 hyper-
tensive patients were randomized to atorvastatin 10mg/day
or placebo and followedup for a mean time of 3.5 years.
Contrary to what was documented among CKD patients,
authors could not detect any eﬀect of statin on arterial
stiﬀness [26].
The eﬀect of antihypertensive agents acting on the renin-
angiotensin-aldosterone system (RAAS)has also been tested.
Edwards and coworkers [17] randomized 112 patients with
stage 2 and 3 CKD and a good blood pressure control
with ACE inhibitors or angiotensin receptor blockers(ARBs)
to spironolactone (25mg) or placebo. After 40 weeks of
treatment, the use of spironolactone reduced both arterial
stiﬀness and left ventricular mass [17].
The role of RAAS on arterial system was also suggested
in a previous study of 2199 hypertensive patients. When
compared to the association of atenolol and thiazide,
amlodipine and perindopril showed a superior reduction of
aortic pulse pressure (an index of arterial stiﬀness) despite
a similar impact on brachial blood pressure [27]. Providing
that aortic pulse pressure was signiﬁcantly associated with
the composite outcome of cardiovascular events and the
development of renal impairment [27], these results suggest
that central artery stiﬀness attenuation may signiﬁcantly
improve survival. In this regard, a study by Guerin and
coworker [28] further corroborates this hypothesis. In this
study, the absence of PWV decrease with treatment with
ACE-I was an independent predictor of all-cause and CV
mortality during follow-up [28].
6.Conclusion
Convincing evidence supports the notion that arterial stiﬀ-
ness is a marker of arterial damage and associated with an
adverse prognosis. These concepts have been validated in
the general population as well as in CKD patients. Although
screening for arterial stiﬀness increase in patients with CKD
might not fulﬁll the WHO’s suggested requirements for early
disease detection [29], preliminary evidence indicates that
the integration of demographic and clinical characteristics
with information derived from arterial stiﬀness assessment
may represent an accurate and cost-eﬀective approach for
individualizing patients’care and treatment. Finally, prelimi-
nary evidenceshows that attenuationofarterial stiﬀness may
be associated with a signiﬁcant improvement in survival.4 International Journal of Nephrology
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